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ABSTRACT
Background. Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and
characterization in critically ill patients has not been reported.
Methods. Single-centre cohort performed from 3 March 2020 to 14 April 2020 in four intensive care units in Bordeaux
University Hospital, France. All patients with COVID-19 and pulmonary severity criteria were included. AKI was defined
using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. A systematic urinary analysis was performed. The
incidence, severity, clinical presentation, biological characterization (transient versus persistent AKI; proteinuria,
haematuria and glycosuria) and short-term outcomes were evaluated.
Results. Seventy-one patients were included, with basal serum creatinine (SCr) of 69 6 21mmol/L. At admission, AKI was
present in 8/71 (11%) patients. Median [interquartile range (IQR)] follow-up was 17 (12–23) days. AKI developed in a total of
57/71 (80%) patients, with 35% Stage 1, 35% Stage 2 and 30% Stage 3 AKI; 10/57 (18%) required renal replacement therapy
(RRT). Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with
persistent AKI developed a median (IQR) urine protein/creatinine of 82 (54–140) (mg/mmol) with an albuminuria/proteinuria
ratio of 0.23 6 20, indicating predominant tubulointerstitial injury. Only two (4%) patients had glycosuria. At Day 7 after
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onset of AKI, six (11%) patients remained dependent on RRT, nine (16%) had SCr >200mmol/L and four (7%) had died. Day 7
and Day 14 renal recovery occurred in 28% and 52%, respectively.
Conclusion. Severe COVID-19-associated AKI is frequent, persistent, severe and characterized by an almost exclusive
tubulointerstitial injury without glycosuria.
Keywords: acute interstitial nephritis, acute kidney injury, acute tubular injury, COVID-19, critically ill patients, renal replace-
ment therapy
INTRODUCTION
Since December 2019, coronavirus disease 2019 (COVID-19) has
infected nearly 5 million people worldwide, leading to more
than 300 000 deaths. Starting in China, it rapidly expanded to
Europe, affecting first Italy, then Spain and France. Globally, it
has resulted in the confinement of nearly 3 billion people [1, 2].
The severe respiratory damages requiring prolonged intubation
have already been described, which are the determinant of in-
tensive care unit (ICU) admission and have resulted in a consec-
utive risk of ICU saturation [3–6].
Acute kidney injury (AKI) is the second most common or-
gan damage in COVID-19 patients previously reported in
China. It is observed in up to 15% of patients, whatever their
need for ICU admission [4]. However, very few data are avail-
able in patients admitted to ICUs, where this incidence should
be significantly higher. According to the first US report of ICU
patients (n¼ 24) [5], it is observed in 20% of subjects; this does
not reflect the first Western European findings, where >50%
of patients could experience AKI (unpublished data). The rea-
son for this is not clearly established. AKI severity and poten-
tial recovery have not been reported. The need for renal
replacement therapy (RRT) may considerably prolong the
length of ICU hospitalization, leading to significant organiza-
tional and economic challenges for health-care systems. In
addition, a high frequency of AKI could result in a very signifi-
cant increase in the number of patients suffering from long-
term chronic kidney disease (CKD) [7].
The hypothesis was that COVID-19-associated AKI is more
severe and common than previously reported, and may be rep-
resented by different clinical presentations including transient
AKI, acute tubular necrosis (ATN) or other types of injury.
Each of these clinical presentations potentially requires a spe-
cific approach. The objective of the study was to describe the in-




This cohort study was carried out in the four ICUs dedicated to
severe COVID-19 patients at the University Hospital of
Bordeaux, France from 3 March 2020 to 14 April 2020. Patients
data were routinely collected in dedicated electronic health
records during their entire hospital stay. According to French
law and the French Data Protection Authority, the handling of
these data for research purposes was declared to the Data
Protection Officer of the University Hospital of Bordeaux. The
study obtained the approval of the Institutional Review Board of
the University Hospital of Bordeaux (declaration number 2020-
14). Patients (or their relatives, if any) were notified about the
anonymized use of their health care data via the department’s
booklet.
Participants
Patients were enrolled if they were aged 18 years, had a posi-
tive polymerase chain reaction for COVID-19 or typical com-
puted tomography findings in patients with a high clinical pre-
test probability of COVID-19 [8], and had severity criteria for ad-
mission to one of the four ICUs. These severity criteria were de-
fined by the need for 4 L/min oxygen therapy (O2) to obtain an
arterial oxygen saturation (SaO2) 94% or arterial partial pres-
sure of oxygen/fraction of inspired oxygen ratio (PaO2/FiO2)
300 mmHg in patients receiving high-flow nasal cannula oxy-
gen. The University Hospital of Bordeaux was confronted with a
far less aggressive epidemic context than those reported in
other French regions or other countries. Therefore, all patients
presenting with this severity were systematically admitted to
ICU except those who had withdrawal orders. No specific
withdrawal policy was applied during this epidemic period.
ICU patients were excluded from this study only if they had
pre-existing end-stage kidney disease defined by the need
for RRT.
Patient management
Patients were treated according to the standard of care. In three
units, hydroxychloroquine (HCL) was administered because of
physicians’ personal decision according to physiopathological
studies suggesting an in vitro efficacy against severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2). The dosage
schedule was per os 400 mg twice a day. at Day 1 and then
200 mg twice a day for 5–10 days. One unit added tocilizumab to
HCL with a single 8 mg/kg infusion. Two units administered
lopinavir/ritonavir (400 mg twice a day in syrup form) at first
and then stopped because of drug shortage. All treatments were
started on the day of admission to ICU. Importantly, no other
modification in COVID-19 critically ill patients’ care occurred,
and treatment administration was dependent on the unit and
not on patients’ characteristics. All patients had Foley
catheterization.
AKI classification
The Kidney Disease: Improving Global Outcomes (KDIGO) defi-
nition was used to define AKI Stages 1, 2 and 3 [9]. Serum creati-
nine (SCr) and urine output were both taken into account. Stage
1: SCr 1.5–1.9 times baseline or diuresis <0.5 mL/kg/h for 6–12 h;
Stage 2: SCr 2.0–2.9 times baseline or diuresis <0.5 mL/kg/h for
12 h; Stage 3: SCr 3 times baseline, initiation of RRT, anuria
12 h or diuresis <0.3 mL/kg/h for 24 h. AKI stage was classi-
fied using the worst SCr or diuresis during the entire ICU stay.
Baseline SCr values corresponded to SCr values at admission
in the case of normal renal function or SCr values from within 6
months in the case of abnormal SCr at admission. All SCr base-
line values could be collected from previous medical records for
patients with abnormal SCr at ICU admission.
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Acute kidney disease (AKD) staging was performed using the
consensus report of the Acute Disease Quality Initiative (ADQI)
16 workgroup [9] and was defined as a condition wherein crite-
ria for AKI Stage 1 or greater persists 7 days after an exposure.
AKD Stage 1: SCr 1.5–1.9 times baseline; Stage 2: SCr 2.0–2.9
times baseline, Stage 3: SCr 3 times baseline or ongoing need
for RRT.
Exposure variables
Information relative to drugs taken before admission, date and
type of the first COVID-19 symptoms, and a medical history of
hypertension, diabetes, chronic heart failure (chronic ischae-
mic, rhythmic, valvular heart disease or heart failure with pre-
served ejection fraction or reduced ejection fraction), stroke,
chronic obstructive pulmonary disease, asthma and peripheral
arterial disease was collected using prospectively recorded data,
and patient or relative questioning. Pre-admission exposure to
non-steroidal anti-inflammatory drugs and renin–angiotensin
system inhibitors was considered if the patient had taken the
drug the week prior to admission. Weight and height were mea-
sured at ICU admission. All other healthcare data were collected
using Metavision ICU (iMDsoft).
The four ICUs of the University Hospital of Bordeaux re-
ceived patients (n¼ 26) transferred from the ICUs of the Metz
Haguenau, Aulnay Sous Bois, Corbeil Essonnes, Mulhouse or
Strasbourg Hospitals in France. They were included whenever
they met the inclusion criteria of the ICU admission cohort.
Health-care data were collected using medical records from the
previous hospital.
Patients chronically exposed to immunosuppressive drugs
or suffering from haematologic malignancies were considered
immunosuppressed.
CKD was defined as an estimated glomerular filtration rate
of <60 mL/min/1.73 m2, using the Chronic Kidney Disease
Epidemiology Collaboration corresponding to CKD Stage 3 or
more according to the KDIGO classification [9].
Fluid balance was the addition of fluid infusion volume, in-
cluding enteral or parenteral nutrition minus diuresis and gas-
trointestinal losses.
Minimum diuresis was defined by the minimum diuresis/kg/
h used for the KDIGO classification.
All blood or urine biological assessments were usually stan-
dardized in ICUs participating in the study and systematically
collected. All biochemical parameters were determined on
Abbot Architect analysers with enzymatic method for creati-
nine and colorimetric bromocresol purple method for albumin.
SCr was measured at least once a day. A urinary analysis was
performed at ICU admission or whenever AKI occurred or dete-
riorated during the ICU stay. Fractional excretion of sodium
(FeNaþ) and fractional excretion of urea (FeUrea) were calcu-
lated as follows: FeNaþ (%) ¼ ([U/P sodium]/[U/P creatinine]) 
100; FeUrea (%) ¼ ([U/P urea]/[U/P creatinine])  100. U/P is uri-
nary/plasma ratio, and urinary osmolarity was measured.
FIGURE 1: Flow diagram. Patients admitted from 3 March 2020 to 14 April 2020 were taken into consideration.
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The AKI day was the first day during which the patient was
eligible for AKI using KDIGO classification.
Outcomes definitions
Since 2017, RRT initiation criteria have been standardized in the
ICUs participating in the study, according to the delayed strat-
egy of the Artificial Kidney Initiation in Kidney Injury (AKIKI)
trial [10]. Patients were eligible for RRT whenever AKI Stage 3 oc-
curred with clinical indications (anuria 72 h, [Kþ] >6 mmol/L or
>5.5 mmol/L after medical correction, acute pulmonary oe-
dema, pH <7.15 in the absence of other causes, or blood urea
>40 mmol/L).
The ICU length of stay was only calculated for patients who
were discharged from the ICU; most of them were transferred to
medical wards or a continuing care unit.
The intubation length was only calculated for the subgroup
of patients who were successfully extubated. If a patient ever
needed to be re-intubated after having been weaned from the
ventilator, the intubation length was calculated as the sum of
the different periods during which invasive mechanical ventila-
tion was required.
Transient AKI was defined by a50% decrease in SCr or a re-
turn of SCr to its baseline value 72 h after AKI [11].
Recovery from AKI was defined as a return of SCr to 125%
above baseline SCr for alive and non-dependent RRT patients
during the ICU stay [12].
Major adverse kidney events (MAKEs) was a composite out-
come defined by an SCr >200% of baseline, need for RRT or
death [13].
Statistical analysis
Statistical analysis was carried out using JMPVR Version 14 (SAS
Institute Inc., Cary, NC, USA, 1989–2007). Descriptive statistics
included mean 6 standard deviation (SD) or median [interquar-
tile range (IQR)] if the variable did not fit a normal distribution.
Quantitative variables were compared using a t-test, and quali-
tative variables were compared using Fisher’s exact test when
only two variables were studied; Pearson’s Chi-squared test was
used for more variables. AKI incidence during ICU hospitaliza-
tion and renal recovery during hospitalization was plotted using
a Kaplan–Meier curve with a 95% confidence interval, and was
censored with death. A value of double-sided P< 0.05 was con-
sidered statistically significant.
RESULTS
From 3 March 2020, 380 patients were admitted in the
University Hospital of Bordeaux for COVID-19. Among them, 45/
380 (12%) patients with severe COVID-19 were admitted to the
ICU in addition to 26 critically ill patients admitted to ICU from
other regions of France, for a total of 71 patients included
(Figure 1). The reason for admission was acute respiratory fail-
ure for 70/71 (99%), with a majority of males—55/71 (77%)—and
a mean age of 61 6 12 years. Time from the onset of first viral
symptoms to ICU admission was 8 (6–10) days. Details on all
baseline characteristics, including blood test results at admis-
sion, are presented in Table 1.
Median follow-up was 17 (12–23) days, and length of ICU stay
was 10 (7–14) days. Intubation was required for 55/71 (77%)
patients for a median duration of 12 (9–17) days. The worst
PaO2/FiO2 was 95 (79–125). Septic shock was rare since norepi-
nephrine infusion rate [maximum 0.16 (0.10–0.37) mg/kg/min]
was low and no lactate level exceeded 2 mmol/L except in two
patients [14]. Four patients died (11%). Table 2 shows the main
follow-up outcomes.
Table 1. Baseline characteristics of patients at ICU admission
Characteristics of Patients n¼ 71
Male, n (%) 55/71 (77)
Age, mean 6 SD 61.2 6 12.2
BMI, mean 6 SD 31.0 6 5.8
Hypertension, n (%) 43/71 (61)
Diabetes, n (%) 21/71 (30)
Heart disease, n (%) 17/71 (24)
OSA, n (%) 9/71 (13)
COPD, n (%) 8/71 (11)
Immunosuppression, n (%) 7/71 (10)
Stroke, n (%) 4/71 (6)
Asthma, n (%) 3/71 (4)
PAD, n (%) 0/71 (0)
NSAID exposure, n (%) 7/71 (10)
RASi exposure, n (%) 23/71 (32)
ACEi exposure, n (%) 15/71 (21)
ARB exposure, n (%) 8/71 (11)
Positive PCR COVID-19, n (%) 68/71 (96)
COVID-19 typical CT scan feature, n (%) 57/71 (80)
Onset of first symptoms to ICU admission
(day), median (IQR)
8 (6–10)
Temperature at ICU admission (C), mean
6 SD
38.02 6 1.25
Admission for respiratory failure, n (%) 70/71 (99)
PaO2/FiO2, median (IQR) 156 (100–233)
MAP (mmHg), mean 6 SD 94 6 19
SAPS II, mean 6 SD 41.2 6 17.1
SOFA score, mean 6 SD 6.4 6 3.9
Respiratory 2.7 6 1.0
Coagulation 0.2 6 0.5
Liver 0.1 6 0.5
Cardiovascular 1.4 6 1.5
Neurologic 1.4 6 1.8
Renal 0.6 6 1.0
Naþ (mmol/L), mean 6 SD 139.8 6 4.6
Kþ (mmol/L), mean 6 SD 4.07 6 0.52
Bicarbonate (mmol/L), mean 6 SD 24.7 6 3.8
D-dimers (ng/mL), mean 6 SD 6284 6 13000
Lymphocytes count (/mm3), mean 6 SD 0.91 6 0.55
Ferritin (ng/ml), mean 6 SD 1914 6 1751
Albumin (g/L), mean 6 SD 20.7 6 5.2
Total protein (g/L), mean 6 SD 65.6 6 7.3
Renal baseline
CKD, n (%) 4/71 (6)
Basal SCr (mmol/L)a, mean 6 SD 68.8 6 20.9
SCr at admission (mmol/L), mean 6 SD 115.6 6 107.7
BUN (mmol/L),vmean 6 SD 10.1 6 7.4
AKI, n (%) 8 (11)
Defined using SCr criteria 6 (75)
Defined using diuresis criteria 2 (25)
aBasal SCr was SCr at admission in the case of normal renal function or SCr
within 6 months in the case of abnormal SCr at admission.
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor
blockers; BMI, body mass index; BUN, blood urea nitrogen; COPD, chronic ob-
structive pulmonary disease; CT, computed tomography; FiO2: fraction of in-
spired oxygen; Kþ, potassium; MAP, mean arterial pressure; Naþ, sodium;
NSAID, non-steroidal anti-inflammatory drug; OSA, obstructive sleep apnoea;
PAD, peripheric arterial disease; PaO2, arterial partial pressure of oxygen; PCR,
polymerase chain reaction; RASi, renin–angiotensin system inhibitor; SAPS,
simplified acute physiology score.
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AKI
At admission, AKI was present in 8/71 (11%) patients. During
their ICU stay, AKI developed in 49 other patients, reaching a to-
tal of 57/71 (80%) patients. The timing of AKI development is
shown in Figure 2A. Stage 1 AKI was observed in 20/57 (35%)
patients, Stage 2 in 20/57 (35%) and Stage 3 in 17/57 (30%); 10/57
(18%) required RRT. Patients with AKI had a higher body mass
index (32 6 6 versus 28 6 5 kg/m2; P¼ 0.04); higher total sequen-
tial organ failure assessment (SOFA) (7 6 3.8 versus 3.9 6 3.3;
P¼ 0.006), renal SOFA (0.7 6 1.1 versus 0 6 0; P< 0.001) and car-
diovascular SOFA (1.6 6 1.5 versus 0.4 6 0.9, P¼ 0.004) scores;
and lower PaO2/FiO2 ratios [93 (76–120) versus 109 (90–227);
P¼ 0.04]. They had similar maximal norepinephrine infusion
[0.16 (0.10–0.39) mg/kg/min versus 0.23 (0.12–0.30) mg/kg/min;
P¼ 0.76], maximal lactate level (1.4 6 0.7 mmol/L versus
1.5 6 0.3 mmol/L; P¼ 0.76), contrast agent infusion [12/57 (21%)
versus 3/14 (21%); P¼ 0.98] and crystalloid infusion during the
first 24 h after admission (3074 6 1577 mL versus 2761 6 905 mL;
P¼ 0.37). Comparisons between patients with or without AKI
are presented in Table 3.
Characterization of AKI
Because two deaths occurred in the first 72 h after AKI, only 55
patients could be assessed to differentiate transient from per-
sistent AKI. Transient AKI was present in only 4/55 (7%)
patients, and persistent AKI was present in 51/55 (93%).
Compared with patients with persistent AKI, patients with tran-
sient AKI had similar basal SCr (69 6 21 mmol/L versus 76 6 23
mmom/L; P¼ 0.62), natriuresis (53 6 40 mmol/L versus
81 6 75 mmol/L; P¼ 0.52), urinary osmolarity (515 6 182 mmol/L
versus 637 6 330 mmol/L; P¼ 0.52), FeNaþ (0.6 6 0.9% versus
0.6 6 0.7%; P¼ 0.96), FeUrea (33 6 12% versus 39 6 11%; P¼ 0.35)
and fluid balance at 72 h after AKI diagnosis (12805 6 6378 mL
versus 8070 6 3732 mL; P¼ 0.29), respectively (Table 4).
Patients with persistent AKI developed a median protein-
uria/creatininuria of 82 (54–140) mg/mmol with an albuminuria/
proteinuria ratio of 0.13 (0.07–0.32). Haematuria was present in
35/51 (69%) patients; leucocyturia was present in 24/51 (47%)
patients. Glycosuria was found in 2/51 (4%) patients.
Renal outcomes
At Day 7 after AKI, 6/57 (11%) patients remained dependent on
RRT, 9/57 (16%) had SCr >200 mmol/L and 4/57 (7%) died, ac-
counting for 19/57 (33%) patients reaching MAKE criteria. Renal
recovery occurred in 28% of patients at Day 7, 52% at Day 14 and
64% at Day 21 (Figure 2B).
DISCUSSION
In this study, the incidence of COVID-19-associated AKI was
higher (80%) than reported previously (3–20%) [4, 6, 15]. Cases
were severe, with 30% Stage 3 and 18% RRT and not transient;
>90% of cases were persistent AKI. The value of urinary indices
to differentiate transient versus persistent AKI in this context
might be questioned. Both high proteinuria and low albumin-
uria were not in favour of a prevalent glomerular injury and
suggest acute tubular injury (ATI), interstitial nephritis (IN) or
both. The very low incidence of glycosuria was not in favour of
Fanconi syndrome. Haematuria and leucocyturia could not be
interpreted by the presence of foley catheter for all patients.
To the best of our knowledge, this is the first study to sys-
tematically explore COVID-19-associated AKI, particularly in
more severe patients. The higher incidence of AKI observed in
this study can be explained in different ways. First, it could be
related to the severity of the disease by an increase in the initial
renal viral charge and/or severe systemic inflammation.
Moreover, the exhaustive collection of basal SCr of ICU patients
could contribute to this higher incidence, providing a more real-
istic spectrum of COVID-19-associated renal injury.
Whether the cause of AKI is ATI, IN or both is debatable.
ATN, the most common form of ATI, is mainly influenced by
haemodynamic parameters and iodinated contrast agents [16].
In this study, the use of these agents was limited (20%). The
haemodynamic instability of patients with AKI was slight due
to high sedation infusion rate [17]. No septic shock was ob-
served and no differences in inflammatory states (C-reactive
protein and ferritin) were observed between AKI and non-AKI
patients. This suggests the possibility of a viral-specific ATI.
SARS-CoV-2 (the virus causing COVID-19) penetrates the cells
via two receptors [Angiotensin-converting enzyme 2 (ACE2) and
Transmembrane protease, serine 2 (TMPRSS2)] [18]. While ACE2
is highly expressed in proximal tubular epithelial cells and in
podocytes, TMPRSS2 is only detectable in the proximal tubule
S3 segment. By infiltrating the renal tubular cell, SARS-CoV-2
might induce ATI. This could explain why 9 out of 26 autopsied
patients in China with COVID-19-associated AKI had primarily
diffused proximal tubular injury, with some frank necrosis and
no glomerular injury [19]. Another post mortem study showed
severe ATI with IN (CD68þ macrophage infiltration of the tubu-
lointerstitium) [20]. However, in these post mortem studies,
patients had less severe renal involvement and may not be rep-
resentative of more severe patients. Pulmonary damages have
been reported as an inflammatory pattern integrated into a cy-
tokine storm syndrome [21]. The frequent association we report
between renal and pulmonary injuries might have several
explanations. First, co-occurrence does not necessarily mean a
common pathway. However, one is left to wonder if infection
with SARS-CoV-2 may result in inflammation or direct viral in-
jury of both organs. Renal biopsies in patients with severe
COVID-19-associated AKI might thus be considered and
Table 2. Main follow-up outcomes
Outcomes n¼ 71
Follow-up (days), median (IQR) 17 (12–23)
ICU length of stay (n ¼ 38)a, median (IQR) 10 (6.7–14.2)
Intubation, n (%) 55/71 (77)
Length of intubation (n ¼ 29)b, median (IQR) 12 (9–17)
Worst PaO2/FiO2, median (IQR) 95 (79–125)
Need for NE infusion, n (%) 52/71 (73)
Maximal dose of NE infusion (mg/kg/min), median
(IQR)
0.16 (0.10–0.37)
Day of NE maximal dose from ICU admission
(days), median (IQR)
4 (1–12)
Maximal lactate level (mmol/L), mean 6 SD 1.5 6 0.7
ICU deaths, n (%) 4/71 (6)
Onset of death from ICU admission (days), me-
dian (IQR)
9 (5–19)
aThe ICU length of stay was only calculated for patients who were discharged
from the ICU, n¼38.
bThe length of intubation was only calculated for patients who were success-
fully weaned from the ventilator, n¼29.
FiO2, fraction of inspired oxygen; ICU, intensive care unit; NE, norepinephrine;
PaO2, arterial partial pressure of oxygen.
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lead to specific anti-inflammatory therapies for IN-
predominant AKI.
While FeUrea and FeNaþ have been previously reported as
relevant for the differentiation of transient AKI from persistent
AKI [11, 22], this was not shown in the current study.
Limitations of our work include the small number of
patients (n¼ 71) and a limited median follow-up period
(2 weeks). These results will have to be confirmed by larger
studies with longer follow-up period.
In conclusion, this study should make physicians aware of
the likely existence of a frequent, severe and specific COVID-19-
associated AKI. The study provides additional insights into the
characterization of AKI: a tubulointerstitial injury without gly-
cosuria. Further work should be carried out promptly in order to
identify and assess specific therapeutic options.
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FIGURE 2: (A) Incidence of AKI during the ICU stay censored with death with 95% confidence interval. (B) Renal recovery during hospitalization censored with death
with 95% confidence interval.
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PaO2/FiO2 at admission, median (IQR) 150 (94–222) 220 (172–249) 0.07
SAPSII, mean 6 SD 42.8 6 16.5 34.4 6 18.3 0.13
SOFA score, mean 6 SD 7 6 3.8 3.9 63.2 0.006
Respiratory 2.8 6 0.9 2.3 6 0.9 0.06
Coagulation 0.2 6 0.5 0.2 6 0.6 0.90
Liver 0.1 6 0.5 0.1 6 0.5 0.99
Cardiovascular 1.6 6 1.5 0.4 6 0.8 0.004
Neurologic 1.5 6 1.8 0.8 6 1.7 0.22
Renal 0.7 6 1.1 0 6 00 <0.001
Specific therapy, n (%)
Hydroxychloroquine 31/57 (54) 9/14 (64) 0.56
Lopinavir–Ritonavir 21/57 (37) 4/14 (29) 0.76
Tocilizumab 5/57 (9) 0/14 (0) 0.57
Crystalloid infusion during the first 24 h (mL), mean 6 SD 3074 6 1577 2761 6 905 0.37
Contrast agent, n (%) 12/57 (21) 3/57 (21) 0.98
Worst PaO2/FiO2, median (IQR) 93 (76–120) 108 (90–227) 0.04
Maximal NE infusion (mg/kg/min), median (IQR) 0.16 (0.10–0.39) 0.23 (0.12–0.30) 0.76
Lactate level at maximal NE infusion (mmol/L), mean 6 SD 1.5 6 0.7 1.5 6 0.3 0.76
C-reactive protein (mg/L) at admission, mean 6 SD 164 6 111 125 6 72 0.12
Ferritin (ng/mL) at admission, mean 6 SD 1873 6 1778 2103 6 1686 0.68
Lymphocytes at admission (/mm3), mean 6 SD 939 6 590 782 6 342 0.20
AKI Stage 1, n (%) 20/57 (35)
AKI Stage 2, n (%) 20/57 (35)
AKI Stage 3, n (%) 17/57 (30)
AKD Stage 1, n (%) 2/57 (4)
AKD Stage 2, n (%) 7/57 (12)
AKD Stage 3, n (%) 9/57 (16)
Total AKD 18/57 (32)
MAKEs, n (%) 19 (33) 0
SCr >200 mmol/L 9/19 (47)
Dialysis at Day 7 6/19 (32)
Death 4/19 (21)
BMI, body mass index; FiO2, fraction of inspired oxygen; MAP, mean arterial pressure; NE, norepinephrine; PaO2, arterial partial pressure of oxygen; SAPS, simplified
acute physiology score.
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Table 4. Comparison between patients with transient versus persistent AKI
Characteristics of Patients Transient AKI (n¼ 4) Persistent AKI (n¼ 51) P-value
SCr (mmol/L) at admission, mean 6 SD) 87 6 27 116 6 106 0.16
SCr (mmol/L) at AKI, mean 6 SD) 81 6 36 147 6 109 0.02
SCr (mmol/L) 48h after AKI, mean 6 SD) 69 6 29 196 6 226 <0.001
Defined using SCr criteria, n (%)






AKI Stage 1, n (%) 1/4 (25) 20/51 (39) 0.18
AKI Stage 2, n (%) 3/4 (75) 16/51 (31)
AKI Stage 3, n (%) 0 15/51 (30)
Fluid balance 48 h after AKI (mL), mean 6 SD 6146 6 2519 8767 6 4429 0.36
Fluid balance 72 h after AKI (mL), mean 6 SD 8070 6 3732 12 805 6 6378 0.29
Minimum diuresis (mL/kg/h), mean 6 SD 0.6 6 0.2 0.5 6 0.3 0.67
Urinary Naþ (mmol/L), mean 6 SD 81 6 75 53 6 40 0.52
Urinary Kþ (mmol/L), mean 6 SD 34 6 22 44 6 21 0.46
Urinary urea (mmol/L), mean 6 SD 291 6 80 327 6 164 0.69
Urinary osmolarity (mmol/L), mean 6 SD 637 6 330 515 6 182 0.52
FeNaþ (%), mean 6 SD 0.6 6 0.7 0.6 6 0.9 0.96
FeUrea (%), mean 6 SD 39 6 11 33 6 12 0.35
UNaþ/UKþ ratio, mean 6 SD 2.3 6 1.6 1.7 6 2 0.54
Proteinuria/creatininuria (mg/mmol), median (IQR) 124 (38–203) 82 (54–140) 0.62
Albuminuria/creatininuria (mg/mmol), median (IQR) 6 (6–8) 9 (5–32) 0.31
Albuminuria/proteinuria (%), mean 6 SD 8 6 6 23 6 20 0.03
Haematuria, n (%) 3/4 (75) 35/51 (69) 1
Leucocyturia, n (%) 1/4 (25) 24/51 (47) 0.62
Glycosuria, n (%) 0 (0) 2/51 (4) 1
RRT, n (%) NR 10/51 (20) NA
Date of RRT initiation, median (IQR) NR 8 (4–10) NA
Indication of RRT initiation, n (%) NR N ¼ 10 NA
Anuria 72h 7/10 (70)
[Kþ] >6 mmol/L 1/10 (10)
pH <7.15 2/10 (20)
Acute pulmonary oedema 0 (0)
Death, n (%) 0 (0) 2/51 (4) 1
Fe, fractional excretion; Kþ, potassium; Naþ, sodium; NA, not available; NR, not relevant; UNaþ/Kþ ratio, urinary sodium/potassium ratio.
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